674 related articles for article (PubMed ID: 27437696)
21. Can we reduce the dosage of biologics in spondyloarthritis?
Olivieri I; D'Angelo S; Padula A; Leccese P; Nigro A; Palazzi C
Autoimmun Rev; 2013 May; 12(7):691-3. PubMed ID: 22940233
[TBL] [Abstract][Full Text] [Related]
22. The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials.
Denis A; Sztejkowski C; Arnaud L; Becker G; Felten R
RMD Open; 2023 Jul; 9(3):. PubMed ID: 37507210
[TBL] [Abstract][Full Text] [Related]
23. Treating to Target(s) With Interleukin-17 Inhibitors.
Lynde CW; Beecker J; Dutz J; Flanagan C; Guenther LC; Gulliver W; Papp K; Rahman P; Sholter D; Searles GE
J Cutan Med Surg; 2019; 23(2_suppl):3S-34S. PubMed ID: 30742778
[TBL] [Abstract][Full Text] [Related]
24. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis.
So A; Inman RD
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):453-471. PubMed ID: 31171315
[TBL] [Abstract][Full Text] [Related]
25. The role of secukinumab in the treatment of ankylosing spondylitis.
Shah R; Perry L; Deodhar A
Immunotherapy; 2015; 7(12):1241-7. PubMed ID: 26595091
[TBL] [Abstract][Full Text] [Related]
26. Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study.
Gehin JE; Goll GL; Warren DJ; Syversen SW; Sexton J; Strand EK; Kvien TK; Bolstad N; Lie E
Arthritis Res Ther; 2019 Nov; 21(1):256. PubMed ID: 31783773
[TBL] [Abstract][Full Text] [Related]
27. Emerging treatment options for spondyloarthritis.
Torgutalp M; Poddubnyy D
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):472-484. PubMed ID: 31171316
[TBL] [Abstract][Full Text] [Related]
28. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis.
Yeremenko N; Paramarta JE; Baeten D
Curr Opin Rheumatol; 2014 Jul; 26(4):361-70. PubMed ID: 24827753
[TBL] [Abstract][Full Text] [Related]
29. Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis:
Bagri NK; King H; Ramanan AV
Expert Rev Clin Immunol; 2024 May; 20(5):435-440. PubMed ID: 38186357
[TBL] [Abstract][Full Text] [Related]
30. Oral treatment options for AS and PsA: DMARDs and small-molecule inhibitors.
Chan J; Gladman D
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):415-426. PubMed ID: 31171312
[TBL] [Abstract][Full Text] [Related]
31. Updated guidelines for the management of axial disease in psoriatic arthritis.
Nash P; Lubrano E; Cauli A; Taylor WJ; Olivieri I; Gladman DD
J Rheumatol; 2014 Nov; 41(11):2286-9. PubMed ID: 25362712
[TBL] [Abstract][Full Text] [Related]
32. Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review.
Eksin MA; Erden A; Güven SC; Armagan B; Ozdemir B; Karakas O; Omma A; Kucuksahin O
Immunotherapy; 2022 Apr; 14(6):401-408. PubMed ID: 35152720
[No Abstract] [Full Text] [Related]
33. Axial spondyloarthritis: thoughts about nomenclature and treatment targets.
Braun J
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S132-5. PubMed ID: 23079005
[TBL] [Abstract][Full Text] [Related]
34. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
35. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies.
McGonagle DG; McInnes IB; Kirkham BW; Sherlock J; Moots R
Ann Rheum Dis; 2019 Sep; 78(9):1167-1178. PubMed ID: 31278139
[TBL] [Abstract][Full Text] [Related]
36. [Current treatment for spondyloarthritis: focus on netakimab. A review].
Karateev DE; Luchikhina EL
Ter Arkh; 2024 Jun; 96(5):543-550. PubMed ID: 38829817
[TBL] [Abstract][Full Text] [Related]
37.
Iwaszko M; Wielińska J; Świerkot J; Kolossa K; Sokolik R; Bugaj B; Chaszczewska-Markowska M; Jeka S; Bogunia-Kubik K
Front Immunol; 2021; 12():631603. PubMed ID: 34177886
[TBL] [Abstract][Full Text] [Related]
38. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis.
Schoels MM; Braun J; Dougados M; Emery P; Fitzgerald O; Kavanaugh A; Kvien TK; Landewé R; Luger T; Mease P; Olivieri I; Reveille J; Ritchlin C; Rudwaleit M; Sieper J; Smolen JS; Wit Md; van der Heijde D
Ann Rheum Dis; 2014 Jan; 73(1):238-42. PubMed ID: 23740234
[TBL] [Abstract][Full Text] [Related]
39. Secukinumab: A Review in Psoriatic Arthritis.
Shirley M; Scott LJ
Drugs; 2016 Jul; 76(11):1135-45. PubMed ID: 27299434
[TBL] [Abstract][Full Text] [Related]
40. Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
Rossini M; Viapiana O; Orsolini G; Fracassi E; Idolazzi L; Gatti D; Adami S; Govoni M
Reumatismo; 2015 Mar; 66(4):285-303. PubMed ID: 25829189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
